Blocking Protein kinase C signaling pathway: mechanistic insights into the anti-leishmanial activity of prospective herbal drugs from  by unknown
PROCEEDINGS Open Access
Blocking Protein kinase C signaling pathway:
mechanistic insights into the anti-leishmanial
activity of prospective herbal drugs from
Withania somnifera
Abhinav Grover1†, Shashank Prakash Katiyar1†, Jeyaraman Jeyakanthan2, Vikash Kumar Dubey3, Durai Sundar1*
From Asia Pacific Bioinformatics Network (APBioNet) Eleventh International Conference on Bioinformatics
(InCoB2012)
Bangkok, Thailand. 3-5 October 2012
Abstract
Background: Leishmaniasis is caused by several species of leishmania protozoan and is one of the major vector-
born diseases after malaria and sleeping sickness. Toxicity of available drugs and drug resistance development by
protozoa in recent years has made Leishmaniasis cure difficult and challenging. This urges the need to discover
new antileishmanial-drug targets and antileishmanial-drug development.
Results: Tertiary structure of leishmanial protein kinase C was predicted and found stable with a RMSD of 5.8Å
during MD simulations. Natural compound withaferin A inhibited the predicted protein at its active site with -28.47
kcal/mol binding free energy. Withanone was also found to inhibit LPKC with good binding affinity of -22.57 kcal/
mol. Both withaferin A and withanone were found stable within the binding pocket of predicted protein when MD
simulations of ligand-bound protein complexes were carried out to examine the consistency of interactions
between the two.
Conclusions: Leishmanial protein kinase C (LPKC) has been identified as a potential target to develop drugs
against Leishmaniasis. We modelled and refined the tertiary structure of LPKC using computational methods such
as homology modelling and molecular dynamics simulations. This structure of LPKC was used to reveal mode of
inhibition of two previous experimentally reported natural compounds from Withania somnifera - withaferin A and
withanone.
Background
Leishmaniasis is an endemic disease prevalent in many
parts of the world; mostly in countries like India, Bangla-
desh, Pakistan, Afghanistan, Nepal, East and North
Africa, and Deserts in western Asia [1]. Leishmaniasis is
responsible for the death of approximately 70,000 people
each year worldwide [2]. It is caused by various species of
intramacrophage protozoan Leishmania like Leishmania
donovani, Leishmania major, Leishmania mexicana and
Leishmania panamensis to name a few, and spread by
the bite of sandfly [1]. Leishmaniasis is becoming the dis-
ease of attention and concern because in the last few dec-
ades L.donovani has developed drug-resistance and
toxicity towards available drugs [3,4]. Hence, it has
become inevitable to identify new drug targets and
to develop novel drugs against L.donovani to cure
Leishmaniasis.
Previous experimental study has shown that methano-
lic compounds from Withania somnifera (ashwagandha)
possess in vitro anti-leishmanial activity [5,6]. Withaferin
A has been identified as one of ashwagandha’s prominent
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phytocompounds. It is a cell permeable steroidal lactone
which has been shown to possess anti-leishmanial prop-
erty [5] apart from many other pharmacological proper-
ties. Withaferin A belongs to a class of compounds from
Withania somnifera collectively known as withanolides.
These exhibit number of other therapeutic activities like
anticancer [7-11], anti-herpetic [12] and neuronal regen-
eration property [13]. Unlike higher eukaryotes, witha-
ferin A has been reported to induce apoptosis in
leishmanial cells by targeting its protein kinase [6].
Protein kinases in mammalian cells are associated with
many important cellular processes like gene activation, cell
differentiation and release of neurotransmitters [6,14,15].
On one hand, the types and role of protein kinases are well
studied in mammalian cells, while on the other hand, only
scarce information is available about protein kinases of
protozoans. Previous studies have proven that protozoan
protein kinases differ from mammalian protein kinases
both structurally and functionally [16]. These differences
between mammalian and protozoan protein kinases render
these kinases as potential drug targets [17]. For the purpose
of ease, protein kinase in Leishmania has been termed as
leishmanial protein kinase C (LPKC) [18]. Although pre-
vious studies have reported the inhibition of LPKC by
methanolic compounds of ashwagandha plant, so far no
study has been carried out which provides the mechanism
of action and structural insights of the inhibition. Structure
of LPKC has not yet been solved experimentally and una-
vailability of this structure of LPKC further limits the
development of drugs against it. Structure-based drug
designing is a popular approach to search inhibitors against
a target protein but it requires information of three dimen-
sional structure of the target [19,20]. In the absence of
experimental tertiary structures of a protein, computational
methods such as homology modeling and threading are
capable of predicting protein structures [21]. In such sce-
nario, computational methods can be used to predict the
structure and active site of LPKC. Probing LPKC’s mode of
inhibition by pharmacologically active compounds of ash-
wagandha will broaden the prospects of drug development
against leishmaniasis and this information can be used to
screen large number of inhibitors against it more accu-
rately and rapidly. Ashwagandha also contains another
important compound known as withanone which is known
to possess antitoxic activity against methoxyacetic acid in
addition to its prominent anticancer properties [22,23].
Though withanone has not yet been tested against leishma-
niasis experimentally, this study provides a computational
proof of its possible inhibitory activity against LPKC.
Computational methods
Homology modeling
1262 amino acid-long protein sequence of LPKC (Acces-
sion no. CBZ31403) was retrieved from NCBI protein
database in FASTA format. Position-Specific Iterated
BLAST against PDB database was used to identify homo-
logous protein structures of LODC [24-27]. There was
complete absence of any homologous structure for the
residual range ~0-660 and ~1030-1262 amino acids.
LPKC sequence ranging from 650-1025 is a conserved
protein sequence and contains the catalytic domain of
serine/threonine protein kinase. Because of unavailability
of homologous structure for initial and last region of
LPKC and highly conserved nature of 650-842 amino
acids, only conserved stretch was considered for model-
ing purpose using homology modeling approach. Crystal
structures of human calcium/calmodulin-dependent pro-
tein kinase type-IV (2W4O) at 2.17 Å resolution and
death-associated protein kinase-1 (2Y0A) at 2.6 Å resolu-
tion were selected as templates for homology modeling.
2W4O had an e-score of 3 × 10-11 and 27% identity with
protein sequence of query with an 87% coverage and
2Y0A showed 2 × 10-5 e-core and 30% identity with 46%
coverage of query. Homology model of LPKC using crys-
tal structure of selected templates was built using multi-
template protocol of MODELLER version 9.10 [28,29].
Discrete Optimized Protein Energy (DOPE ) [30] was
applied to refine the loops of the generated models. Mod-
els were accessed on the basis of Modeler Objective
Function, DOPE scores, verify3D score [31,32] and
ERRAT score [33]. To select a model out of the several
models generated by MODELLER, dope energy profile
was generated for templates and models. Model posses-
sing closest DOPE energy profile with template was
selected for further studies. Selected model was further
refined and stabilized using Molecular Dynamics (MD)
simulations [34].
Molecular dynamics simulations
Desmond Molecular Dynamics system [35,36] with Opti-
mized Potentials for Liquid Simulations (OPLS) all-atom
force field 2005 [37,38] was used to perform MD simula-
tions of all proteins and ligand-bound complexes. Mod-
eled protein structure and structures of protein-ligand
complexes were first prepared using protein preparation
wizard of Maestro interface [36]. Prepared structures
were then uploaded in Desmond set up wizard for MD
simulations. Preparation of protein structure includes the
addition and optimization of hydrogens, generation of
disulphide bonds, and removal of water molecules and
capping of terminals. Prepared protein molecules were
solvated with TIP4P water model in a cubic periodic
boundary box to generate required systems for MD simu-
lations. Systems were neutralized using appropriate num-
ber of counterions. The distance between box wall and
protein complex was set to greater than 10Å to avoid
direct interaction with its own periodic image. Energy of
prepared systems for MD simulations was minimized up
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to maximum 5000 steps using steepest descent method
until a gradient threshold ( 25 kcal/mol/Å) is reached,
followed by L-BFGS (Low-memory Broyden-Fletcher-
Goldfarb-Shanno quasi-Newtonian minimizer) until a
convergence threshold of 1 kcal/mol/Å was met. The sys-
tems were equilibrated with the default parameters pro-
vided in Desmond. Further MD simulations were carried
on the equilibrated systems for desired period of time at
constant temperature of 300 K and constant pressure of
1 atm with a time step of 2fs. During the MD simulations
smooth particle mesh Ewald method was used to calcu-
late long range electrostatic interactions. Nine Å cut-off
radius was used for coulombic short range interaction
cutoff method. The modeled LPKC protein was prepared
for MD simulations using the parameters described
above. The system was then continuously simulated for a
long time period of 15ns. Stability of docking of ligands
into the modeled proteins were also investigated using
MD simulations. All protein-ligand complexes were
simulated for 10ns time period using similar parameters
as described above.
The root mean square deviation (RMSD) for both the
modeled protein and the docked ligands within the bind-
ing pocket of protein were calculated for the entire simula-
tions trajectory with reference to their respective first
frames. ROG and H-bond analyses were carried out for all
the frames of 15ns MD simulation of LPKCL. The hydro-
phobic interactions and H-bonds were calculated using
Ligplot program [39] where H-bonds were defined as
acceptor-donor atom distances of less than 3.3 Å, hydro-
gen-acceptor atom distance of maximum 2.7 Å and accep-
tor-H-donor angle greater than 90°. During the MD
simulations, H-bond fluctuations of ligand with protein
were calculated using VMD software [40].
Binding site identification
Binding site and catalytic site of LPKC were present in ser-
ine/threonine kinase domain, which is a conserved
sequence. Same domain was also present in human cal-
cium/calmodulin-dependent protein (2W4O) which has
an experimentally solved tertiary structure along with an
inhibitor. Template structure of 2W4O was superimposed
over the modeled structure to know the location of con-
served binding site of LPKC. To confirm the binding site
of LPKCL, detected by superimposition, structure of
LPKCL was submitted to CASTp server [41] and SiteMap
module [42]. Both CASTp and SiteMap confirmed the
accuracy of predicted binding site as the binding site
revealed by superimposition located within the largest and
highest ranked cavity.
Virtual molecular docking of ligands with LPKC
Structure files of withaferin A [PubChem:265237] and
withanone [PubChem: 21679027] were retrieved from
the PubChem Compound database. Structure files of
both the ligands were prepared using LigPrep’s ligand
preparation protocol [43]. LigPrep improved the dataset
of small molecules by generation of tautomeric, stereo-
chemical and ionization variations, as well as by perform-
ing energy minimization and flexible filtering. Similarly,
modeled protein structures were also prepared before the
docking steps using Schrödinger’s protein preparation
wizard [44]. Protein preparation implicated the addition
and optimization of hydrogen atoms, removal of bad con-
tacts, optimization of bond lengths, creation of disulphide
bonds, capping of protein terminals, and conversion of
selenomethionine to methionine. A grid was generated at
the predicted binding site of modeled structure as an
essential step for docking using the Glide docking mod-
ule of Schrödinger [45,46].
Prepared natural compounds were virtually docked
against modeled LPKC protein at desired grid coordinates
using Glide model’s XP docking protocols [45]. Stability of
the top scoring docked conformations obtained from glide
XP docking, was inspected using MD simulations. All the
Glide docking studies were performed on Intel Core 2
Duo CPU @ 3 GHz of HP origin with 1 GB DDR RAM.
Schrodinger 9 Maestro interface was compiled and run
under Ubuntu 32 bits operating system. All the MD simu-
lations studies were performed in GPU server Intel (R)
Core (TM) i7 CPU 930, with 4 GB DDR RAM.
Prime/MM-GBSA binding-free energy calculation
Binding free energies of complexes were calculated using
Prime/MM-GBSA method [47-49]. Output post-viewer
files of the XP docking protocol were used for the calcu-
lation of free energy of binding by Prime/MM-GBSA
protocol. The binding free energy ΔGbinding was esti-
mated using following equation:
Gbinding = ER:L − (ER + EL) + Gsoly + GSA
where ER:L is the energy of the complex, ER + EL is
sum of energies of the receptor and ligand in unbound
state, ΔGsolv is the difference in the GBSA solvation
energy of the complex and sum total of solvation ener-
gies of unbound receptor and ligand. ΔGSA is the differ-
ence in surface area energies of the complex and sum
total of surface area energies of unbound receptor and
inhibitor. OPLS-AA force field [38] and GB/SA conti-
nuum solvent model were used to calculate necessary
energies of the complexes.
Results and discussion
LPKC protein structure modeling and active site
prediction
Two homologous X-ray crystal structures of human cal-
cium/calmodulin-dependant protein kinase and death
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associated protein kinase-1 were used as templates to
predict the tertiary structure of LPKC protein. Predicted
protein contained all the residues in allowed regions on
Ramachandran plot and showed ~70% ERRAT score.
Low resolutions of the template structures were the
probable cause of slightly low ERRAT score of LPKC
structure. Hence modeled protein was stabilized by MD
simulations technique. LPKC is a kinase protein which
possesses a conserved active site similar to other protein
kinases. However, primary structure of LPKC is dis-
tinctly related to mammalian eukaryotic kinases, LPKC
protein tertiary structure aligned well with human
calcium/calmodulin-dependant protein kinase protein
structure. Structural alignment of LPKC with 2W4O pro-
tein structure identified the plausible active site of LPKC
protein which was further confirmed using cavity analysis
server CASTp and active site identification software Site-
Map. CASTp and Sitemap reported the presence of
Asp666, Arg667, Gln669, Arg670, Glu687, Glu689,
Gln691, Asn710, Val711, Thr712, Ala713, Leu714,
Met728, Glu729, Ala731, Asp778, and Ser781 residues
around the highest scoring cavity [Additional File 1].
Molecular dynamics simulations of modeled LPKC protein
To analyze the stability of predicted protein, RMSD of its
backbone was plotted as the time dependant function of
MD simulations [Figure 1]. Fluctuation in backbone of
modeled protein during the simulations was recorded up
to 5.87 Å. After 5ns of MD simulations, backbone was
found to fluctuate around 5Å which persisted till the end
of 15ns simulation. The standard deviation (SD) in RMSD
for whole simulation process was found as 0.97 which was
comparatively higher than 0.3 for the last 10 ns of simula-
tion time. These data suggest that protein had more flex-
ible backbone in the beginning of the MD simulations but
as the simulations continued, protein tend to acquire a
higher stable configuration. A low RMSD throughout the
MD simulation and consistent RMSD at the last of MD
simulation indicated that the predicted tertiary structure
of LPKC had acquired a stable folding conformation. Mea-
sure of the radius of gyration (ROG) is considered as an
indicator of compactness of the protein structure [50].
Hence, variation in ROG values of protein represented the
variation in the compactness in the protein structure
along the simulation.
Modeled protein had ROG value of around 18 Å before
the simulation. ROG fluctuated slightly during initial 2 ns
of simulations followed by higher fluctuations up to 7 ns
[Figure 2]. After 7 ns, protein ROG settled around 19 Å,
which is 1Å higher than the initial ROG value. Higher
ROG of simulated structures than the initial modeled pro-
tein indicated that protein has expanded during the MD
Figure 1 RMSD trajectory of the modeled LPKC protein backbone during the 15ns long MD simulations. Duration of MD simulations is
scaled on X-axis and Y-axis represents the RMSD deviation of protein structure in Å.
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simulations in order to acquire more stable conformation.
Increase in ROG can be clearly observed when initial and
final structures are superimposed on each other [Figure 3].
Although ROG graph indicated that there has been an
increase in the inter-atomic distances of protein during
the simulations, consistent ROG of 19Å during the last 8
ns confirmed development of stable protein conforma-
tions. Intra-Hbonds of a protein during the MD simula-
tions can provide important information about the
stability of protein. Intra-Hbond profiling of LPKC protein
[Figure 4] indicated that protein conformations during the
last 8 ns had almost equal number of H-bonds as the
starting conformation. It is clear from the Intra-Hbond
graph [Figure 4] that all conformations of these 8 ns tra-
jectory had equal number of H-bonds, which is consistent
with respect to the RMSD graph of LPKC protein and
supporting the fact that LPKC acquired a stable conforma-
tion during later part of the simulations. Considering all
Figure 2 RMSD in the ROG of LPKC protein during the 15ns long MD simulations. Duration of MD simulations is scaled on X-axis and Y-
axis represents the RMSD deviation of protein structure in Å.
Figure 3 All atom superimposition of modeled LPKC protein structure before and after the simulation. Helices (blue and yellow), sheets
(red and green) and loops (black and brown) are shown in different colors for first and last frame respectively.
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above observations in ROG, RMSD and intra H-bonds
profiling collectively, it can be said that modeled structure
was not one of the most stable confirmation of LPKCL,
which is why it deviated from its native structure by ~5Å
during the MDsimulation. However, after 7 to 8 ns of MD
simulation, LPKCL reached to that conformational state
which was more stable than the previous state hence after
7 or 8ns MD simulations, structure of LPKCL did not
deviated further. The structural changes in LPKCL protein
caused expansion of the protein structure, as suggested by
the increased ROG of more stable conformations.
Root Mean Square Fluctuation (RMSF) of all the resi-
dues was calculated during the 15ns MD simulations as
well as for last 8ns to locate the regions of higher flexibility
in the protein. In RMSF graph of LPKC for all frames
[Figure 5], we can see that the region between residues
15-20, 90-100 and 150-160 have highest deviation during
the MD simulations. Same pattern was observed in the
RMSF graph during the last 8ns [Additional File 2] which
was the stable phase of LPKCL MD simulations. These
regions of higher variability belong to loop secondary
structure of LPKC protein. It is a well known fact that
loop region tends to be more flexible than other part of
protein. During the 15 ns MD simulations of LPKC pro-
tein, a separate analysis to calculate the deviation in only
the loop regions of protein revealed that these are the
regions of higher flexibility of around 6.80 Å. Hence, it is
clear from above analysis that high RMSF of few part of
protein is caused by the loop structures.
Virtual docking of protein with withaferin A and
withanone
Prepared structures of withaferin A and withanone were
docked with stabilized structure of LPKC and both
Figure 4 Variation in number of Intra-H-bonds during the 15ns MD simulations of LPKC.
Figure 5 Root Mean Square Fluctuation (RMSF) of all residues of LPKC protein during the MD simulations.
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showed almost equal binding affinity with LPKC. Witha-
ferin A and withanone bound to LPKC protein with a
Gide XP score of -6.01 and -6.41 [Table 1]. Withaferin A
has already been reported to bind with LPKC protein by
experimental studies [6]. Figure 6 shows both these ligands
being bound at their respective binding pockets during the
docking. As scoring functions of docking programs are
not exclusively reliable [51], validation of the docking
results are needed to be performed by other reliable
approaches such as free energy calculations and MD simu-
lations of docked complexes. PRIME Free energy of bind-
ing for withaferin A-LPKC complex was measured as
-28.47 kcal/mol while -22.57 kcal/mol for withanone-
LPKC complex. Contrary to the docking scores, withaferin
A was found to show higher binding affinity with LPKC as
compared to withanone. There was less difference
between the values of docking score and between values of
free energy, indicating that both withaferin A as well as
withanone bind to LPKC with almost equal affinity.
Molecular dynamics simulations of complexes
Stability of both the natural compounds in the binding
pockets of LPKC was further analyzed by MD simulation.
RMSD analysis of withaferin A during 10 ns simulations
showed that withaferin A altered its configuration by 1Å
at very beginning of the simulation and maximum RMSD
of 1.36 Å was noticed at 7.7 ns and that too for just one
frame. After the initial deviation, withaferin A did not
deviate further and showed consistent RMSD of around
1Å throughout the simulation process indicating that
withaferin A had acquired a very stable conformational
state.
Withanone showed higher RMSD as compared to with-
aferin A during the 10 ns MD simulations [Figure 7].
Withanone deviated by 1.5 Å after ~1.5 ns MD simula-
tions with a maximum RMSD of 2.2 Å. After 1.5 ns simu-
lation, Withanone showed consistent RMSD of around
1.5 Å throughout the MD simulations which points
towards its stability during the simulations.
Interaction analysis of withaferin A and withanone with
LPKC protein
After docking, both withaferin A and withanone were able
to bind with the residues around active site of LPKC. The
interaction profile of both natural compounds with LPKC
protein residues has been described in Table 2. Withaferin
A interacted with Thr712, Ala713, Glu729 and Asn778 via
H-bonds and formed hydrophobic interactions with
Arg667, Leu703, Leu714, Met728, Ala731, Thr781 and
Cys789 residues of LPKC [Figure 8A and Additional File
3]. After the simulations of withaferin A-LPKC complex,
withaferin A interacted with Ala713 via H-bonds and with
Leu704, Thr712, Met728, Glu729, Ala731, Gln735,
Thr781, Ala783, Cys789 and Asp790 by hydrophobic
intractions [Figure 8A]. H-bond between O5 of withaferin
A and O of Ala713 was conserved during the simulation
with bondlength between 2.79 Å to 2.84 Å, indicating the
stability of this bond. Stable interactions such as H-bonds
and hydrobhobic interactions between protein and ligand
strengthen the binding affinity. Similar to H-bonds, many
hydrophobic interaction were also persistent during the
simulation such as those with Thr712, Met728, Gly729,
Ala731 and Thr781. Most of the residues involved in
hydrophobic interactions and prefer to form van der
Table 1 XP Docking scores and Binding energies of LPKC with natural compounds
Complex XP Glide Score Prime/MM-GBSA binding-free energy (dG)(kcal/mol)
(BeforeMDS/After MDS)
Withaferin A-LPKC complex -6.01 -28.47/-17.97
Withanone-LPKC complex -6.41 -22.57/-18.31
Figure 6 Docking complexes of LPKC with natural compounds A) Withaferin A within the binding pocket of LPKC after virtual
molecular docking. B) Withanone within the binding pocket of LPKC after virtual molecular docking. Both ligands are shown to occupy the
binding site.
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Waals contacts. These are the residues around the active
site of LPKC and occupation of binding sites of these resi-
dues by ligand instead of its natural substrate will lead to
inhibition of protein function. There was loss of few
hydrogen bond interactions between withaferin A and
LPKC protein during the simulations but all those residues
which were interacting via H-bonds previously, were
found to form hydrophobic interactions after the MD
simulations. Free energy of binding calculated for the last
frame of MD simulations of withaferin A-LPKC complex,
was -17.97 Kcal/mol which was lower than the pre-MD
simulations complex. These results indicated that there
has been changes in binding affinity of withaferin A during
the MD simulation. It is clear from RMSD graph of witha-
ferin A [Figure 7] that there has been a slight change in
the conformation of withaferin A during the MD simula-
tions in order to stabilize the ligand within the binding
pocket of LPKC. Though the process of stabilization led to
the disappearane of few hydrogen bonds, there has been
substantial increase in the hydrophobic interactions.
Superimposition of initial frame over last frame of witha-
ferin A-LPKC complex revealed that conformational
change in withaferin A structure has been brought by cer-
tain part of it which was involved in H-bond interaction
[Figure 8B]. Probably, change in its conformation within
the binding pocket of LPKC was caused by loss of H-
bonds between certain parts of withaferin A and protein.
Withanone was forming H-Bonds with Ala713 and
Glu729 after the XP docking and before MD simula-
tions. After the simulations, H-bond with Ala713 disap-
peared while Glu73 was still in contact with withanone
via H-bond [Figure 9A]. Residues Arg667, Gln669,
Glu689, Leu703, Thr712, Leu714, Met728 and Ala731 of
LPKC formed hydrophobic interactions with withanone
after the docking but only residues Gln669, Thr712,
Met728, and Ala731 were found in contact with witha-
none post MD simulations [Figure 9A and Supplemen-
tary Additional File 4]. RMSD analysis of withanone
during withanone-LPKC MD simulations indicated
change in withanone’s conformation by 1.5Å which per-
sisted till the end of the simulations, as can be clearly
seen by the superimposition of pre-MD simulations con-
formation of withanone-LPKC complex over post-MD
simulated conformation [Figure 9B]. Withanone was
found more flexible than withaferin A during the MD
simulations which can be seen during the RMSD analy-
sis of withanone and comparison of interaction profile
before the simulation and after the simulation by LigPlot
analysis. One H-bond disappeared during the simulai-
tons of withanone- LPKC complex. However, H-bond
between O atom of Glu739 and O24 of withanone was
conserved during the simulation with same bond length
of ~3.07 Å. Many hydrophobic interactions between
withanone and LPKC active site residues were also
Figure 7 RMSD trajectory of the withaferin A in withaferin A-LPKC complex (red) and withanone in withanone-LPKC complex (green).
Duration of MD simulations is scaled on X-axis and Y-axis represents the RMSD deviation of protein structure in Å.
Table 2 Interaction profile of LPKC with natural compounds
Type of
Interaction
Withaferin A (before MD) Withaferin A (after MD) Withanone (before MD) Withanone
(after MD)
H-bonds Thr62, Ala63, Glu79, Asn128 Ala63 Ala63, Glu79 Glu79
Hydrophobic Arg17, Leu53, Leu64, Met78,
Ala81, Thr131, Cys139
Leu54, Thr62, Met78, Glu79, Ala81, Gln85,
Thr131, Ala133, Cys139, Asp140
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Figure 8 Interactions between LPKC and withaferin A drawn by Ligplot. Figure shows the changes in interactions and conformation of
bound withaferin A with LPKC during 10ns MD simulations. A) Change in interaction profile of withaferin A-LPKC complex during the MD
simulations. B) Superimposed withaferin A-LPKC complex structures before the simulation (red) and after the simulation (green). Blue circles
specify the regions of conformational change in withaferin A structure.
Figure 9 Interactions between LPKC and withanone drawn by Ligplot. Figure shows the changes in interactions and conformation of
bound withanone with LPKC during 10ns MD simulations. A) Change in interaction profile of withanone-LPKC complex during the MD
simulations. B) Superimposed withanone-LPKC complex structures before the simulations (red) and after the simulations (green).
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found persistent during the simulations such as those
with Glu669, Thr712, Met728 and Ala731. Perseverance
of interaction between protein and ligand during the
simulations kept withanone intact within the binding
pocket of LPKC protein. Post MD simulations, free
energy of withanone-LPKC complex was found to be
-18.31 Kcal/mol indicating a slight fall in the binding
affinity [Table 1]. This data suggests that during the
MD simulations, withanone lost few interactions with
LPKC which led to change in its conformation and
caused lowering of binding affinity but finally resulted in
acquiring a stable conformation.
Though both withaferin A and withanone were found
stable within the binding pocket of LPKC during the MD
simulations, higher RMSD was observed for withanone as
compared to withaferin A during the MD simulation but
both had acquired a conformation which was not deviat-
ing any longer at the end of MD simulation. There was
not a noticeable difference between the docking score of
Withaferin A and Withanone after the docking and after
the MD simulations. Both withaferin A and withanone
were also found to interact with same residues of the
active site after the docking process either via H-bonds or
hydrophobic interactions, thus validating the accuracy of
predicted binding pocket of LPKC and also confirming the
inhibitory nature of both natural compounds against the
kinase. Comparison of final binding free energies of LPKC
complexes with withaferin A and withanone suggested
that both show almost similar free energies of binding
[Table 2].
Conclusions
Withaferin A and withnone are two pharmacologically
active natural products from the medicinal plant Witha-
nia somnifera. Withaferin A has been reported to exhi-
bit antileishmanial properties in previous studies. We
analyzed the inhibitory property of withaferin A as well
as that of withanone at the molecular level. We modeled
an important enzyme of leishmania - LPKC using com-
parative homology modeling and virtually docked witha-
ferin A and withanone with it. Both withaferin A and
withanone were found to inhibit LPKC protein with
almost equal affinity. Withanone has not yet been
experimently proven to inhibit LPKC protein before.
The present study suggests that these two natural pro-
ducts can be potential candidates for checking Leishma-
niasis by inhibiting LPKC. By this study we provide
structural insights of the inhibitory action of withaferin
A and withanone against LPKC.
Additional material
Additional File 1: Active site of LPKCL identified by superimposed
ligand and SiteMap analysis. Superimposed ligand (DKI 1338) over
LPKCL from protein 2W4O is shown in CPK molecular representation.
Mesh like structure is the top predicted site by SiteMap software. It is
clear from the picture that superimposed ligand lies perfectly within the
predicted binding pocket. Same binding pocket was used for the grid
generation. (*.jpg).
Additional File 2: RMSF graph generated only for last 8ns MD
simulation. (*.jpg).
Additional File 3: WithaferinA is bound at the binding pocket of
LPKCL. A) Withaferin-A surrounded by active site residues within its
correct binding site. B) A ligand-receptor interaction diagram is shown to
look at interacting residues within the radius of 4 Å. (*.jpg).
Additional File 4: A view of bound Withanone at the binding
pocket of LPKCL. A) Withanone surrounded by active site residues
within its correct binding site. B) A 2D ligand-receptor diagram is shown
to look at interacting residues within the radius of 4 Å. (*.jpg).
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